CHICAGO (GenomeWeb) – Envisagenics, a startup focused on aiding drug discovery by applying artificial intelligence to gene sequences, has closed a $2.4 million seed round of venture capital.

The lead investors are mostly women, including Daniella Kranjac, managing director of Dynamk Capital; Shana Fisher, founder of Third Kind Venture Capital; and Gillian Sandler, of New York biotech investment company Cosine, the firm said. Envisagenics also received funding from Peter Thiel's Breakout Labs and from the New York State Innovation Venture Capital Fund.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.